Relapsed / Refractory
Studies GROUPED
BY:
 TOPIC
SEARCH Drug
Resistance and Lymphoma in ClinicalTrials.gov |
Clinical
Trials for Refractory Lymphoma
Goal: Treating the disease using investigational
therapies or new combinations of
therapies that that may overcome
drug resistance. NOTE: By definition, clinical
trials are investigational, and it is therefore
not known if the
goals of treatments will be realized.
Monoclonal Antibody
Monoclonal
antibodies are man-made antibodies
(proteins) that target receptors on lymphoma cells.
Return to top
 |
|
| *
Condition:
B-cell lymphomas, including CLL
Rationale
and goal: "Drugs
used in chemotherapy, such as fenretinide, work in different ways
to stop the growth of cancer cells, either by killing the cells or
by stopping them from dividing. Monoclonal antibodies, such as
rituximab, can block cancer growth in different ways. Some find
cancer cells and kill them or carry cancer-killing substances to
them. Others interfere with the ability of cancer cells to grow
and spread. Giving fenretinide together with rituximab may kill
more cancer cells.
PURPOSE: This phase I/II trial is studying the side effects and
best dose of fenretinide and to see how well it works when given
together with rituximab in treating patients with B-cell
non-Hodgkin's lymphoma."
* Fenretinide (4-HPR) is a retinoid (vitamin A) analogue with
antitumor and chemopreventive activities. In a mouse model,
Fenretinide showed synergy with Rituxan.
TOPIC SEARCH
Mechanisms - PubMed
TOPIC SEARCH Outcome data - Medscape |
PubMed
TOPIC SEARCH
Safety or Toxicity - PubMed
|
potential next generation anti-cd20 antibody
| AME-133v
(modified anti-cd20 antibody)
Condition: Relapsed follicular lymphoma, or Refractory cd-20 positive NHL
with "low affinity form of Fc?RIIIa (F/F or F/V at position 158) as determined by FcR genotyping; "
Rationale and goal: The protein engineering of AME-133v
is hypothesized to result in an anti-CD20 therapy with greater potency and efficacy in all patients, but
particularly in genetically defined subpopulations that respond poorly to rituximab because they express a low
affinity version of the Fc receptor on their immune effector cells.
A monoclonal antibody that has
increased binding for this receptor should be more effective in stimulating effector cell killing and thus
improve response to the antibody. This study is designed to provide evidence of the safety and a preliminary
understanding of the efficacy of AME 133v..
Also see: Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower
concentrations and more effectively than rituximab - bloodjournal.org
TOPIC SEARCH
Mechanisms - PubMed
|
potential next generation anti-cd20 antibody
|
Condition:
 | Relapsed or refractory follicular
lymphoma grade I-II
| Tumor verified to be CD20 positive
| CT scan showing demarcated lesions |
| |
Rationale and goal: The
purpose of this trial is to determine the safety and efficacy of
HuMax-CD20 as a treatment for
Follicular Lymphoma (FL).
AND:
Rationale and goal: The
purpose of this trial is to determine the safety and efficacy of
HuMax-CD20 as a treatment for
|
Novel Chemotherapy Agents
Monoclonal
antibodies are man-made antibodies (proteins) that target receptors on
lymphoma cells.
Return
to top
|
Treanda™ (Bendamustine)
Condition: Non-Hodgkin's Lymphoma refractory to Rituxan
Rationale and goal: This drug provides unique mechanisms that
may overcome drug resistance.
TOPIC SEARCH
Mechanisms - PubMed
TOPIC
SEARCH Outcome data - ASCO
| Medscape |
PubMed
TOPIC SEARCH
Safety or Toxicity - ASCO
| PubMed
|
novel
chemotherapy agent - similar to anthracyclines
Return
to top
Novel Targeted Agents
Drugs
that target pathways that may have high specificity to Lymphoma cells.
Return
to top
combining novel
chemo and targeted agents
Return
to top
Novel Immunotherapy
Protocols
experimental
ways to activate the immune system to target Lymphoma cells.
Return
to top
|
Intratumoral
Injection of CPG 7909, Combined With Low dose Local Radiation
NOTE: Study closed as of March 2008, might reopen
before end of year.
Condition: low-grade B-cell lymphoma of any initial
stage or mycosis fungoides of stage IB-IVA. B-cell lymphoma
patients must have failed at least one prior treatment. Mycosis
fungoides patients must have failed or have been intolerant of
at least 2 topical or one systemic treatment.
|
combining radiotherapy with radioimmunotherapy
combining
targeted agents with radioimmunotherapy
utilizing
genetically altered t-cells to target lymphoma cells
utilizing
genetically altered t-cells to target lymphoma cells
novel immune modulating / targeted agent
combines Rituxan
with an immune modulating agent
combines a targeted
agent with rituxan immunotherapy
combines
radioimmunotherapy with monoclonal antibody to treat challenging
CNS lymphoma
combines Rituxan and
Radioimmunotherapy with an immune adjuvant
combines
Radioimmunotherapy with a second agent in T-cell and Hodgkins
lymphomas
adoptive
immunotherapy in EBV-positive lymphomas
Novel Chemo-immunotherapy protocols
Return
to top
Return
to top
Stem Cell Transplant (SCT)-based protocols
Return
to top
utilizing cord blood
for stem cell graft
|
TOPIC SEARCH Cord blood derived Stem Cell transplantation PubMed
standard SCT with
cord blood derived cells
Umbilical
Cord Blood Transplantation
Conditions:
High risk childhood non-Hodgkin's lymphoma;
Graft Versus Host
Disease;
Leukemia;
Lymphoma;
Myelodysplastic (MDS) and
myeloproliferative diseases
|
utilizing graft
versus lymphoma affect
| SCT
Donor
Stem Cell Transplant
Conditions:
Childhood Hodgkin's lymphoma;
Childhood
non-Hodgkin's lymphoma; Leukemia;
Lymphoma; myelodysplastic
and myeloproliferative diseases - (eligible if relapse from
Auto SCT)
|
the goal of
treatment is to consolidate SCT with investigational vaccine
therapy
Return
to top
Radioimmunotherapy
and Stem Cell Transplant
Return
to top
Radioimmunotherapy as
part of conditioning for Stem Cell Transplantation
|
![PubMed](http://www.google.com/custom?hl=en&lr=&ie=ISO-8859-1&cof=AWFID%3A4452213b291e6613%3BL%3Ahttp%3A%2F%2Fwww.lymphomation.org%2Fimages%2Flymphomation.org.gif%3BLH%3A36%3BLW%3A255%3BBGC%3A%23FFFFFF%3BT%3A%23000000%3BLC%3A%230000CC%3BVLC%3A%230000CC%3BALC%3A%230000CC%3BGALT%3A%23008000%3BGFNT%3A%23000000%3BGIMP%3A%23000000%3BDIV%3A%230000CC%3BLBGC%3A%23FFFFFF%3B&q=site%3Awww.ncbi.nlm.nih.gov+"FcR genotyping"+ antibody" +mechanism&btnG=Search){kind=link}
